Metabolic Dysfunction-Associated Steatotic Liver Disease MASLD: Jordan's Perspective Based on Knowledge and Attitude Determinants

被引:0
|
作者
Alqudah, Omar [1 ]
Alshahwan, Hamzeh Feras [2 ]
Alsamhouri, Jehad Feras [2 ]
Yamin, Saif [2 ]
Kaffaf, Ahmad [2 ]
Alassaf, Mohannad [2 ]
Alwarawrah, Zaid [3 ]
机构
[1] Univ Jordan, Jordan Univ Hosp & Sch Med, Dept Med, Div Hepatol & Gastroenterol, Amman, Jordan
[2] Univ Jordan, Sch Med, Amman, Jordan
[3] Mutah Univ, Sch Med, Al Karak, Jordan
关键词
nonalcoholic fatty liver disease; NAFLD; MASLD; hepatic steatosis; liver health; patient education; public health awareness; medical literacy; Metabolic Dysfunction-Associated Steatotic Liver Disease; PREVALENCE; OBESITY; RISK;
D O I
10.2147/RMHP.S481401
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose: The most prevalent chronic liver disease in both developed and developing nations is Metabolic dysfunction-associated Steatotic Liver Disease (MASLD). The condition increases the risk of comorbidities and liver-related morbidity and mortality. The public's awareness and medical personnel's understanding are essential in creating countermeasures to stop the disease's spread; a positive attitude is essential for early screening. This study aimed to explore the knowledge and attitudes of Jordanians living in Amman toward MASLD to determine the public's awareness and medical personnel's understanding of the disease. Materials and Methods: A cross-sectional study was conducted using an online self-administered questionnaire that included 5 items for knowledge and 8 for attitude. Demographic questions were also included to further examine how demographic factors affected knowledge and attitude. Results: Among 906 responders, (63.4%) were females, and (36.6%) were males. The majority age group was 18-30 (56.2%). Only 49.5% had previous knowledge of MASLD, (44.6%) believed they were at risk of developing it. There is a statistical significance between age, gender, educational level, and having a good knowledge of MASLD and a positive attitude towards it (p<0.05). Conclusion: Generally, Jordan's population has a fair knowledge of MASLD and a positive attitude towards it. Warranting more research into the reasons behind it, and more awareness campaigns.
引用
收藏
页码:2483 / 2491
页数:9
相关论文
共 50 条
  • [41] Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
    Sandireddy, Reddemma
    Sakthivel, Suganya
    Gupta, Priyanka
    Behari, Jatin
    Tripathi, Madhulika
    Singh, Brijesh Kumar
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [42] Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents
    Maldonado-Rojas, Andrea del Carmen
    Zuarth-Vazquez, Julia Maria
    Uribe, Misael
    Barbero-Becerra, Varenka J.
    ANNALS OF HEPATOLOGY, 2024, 29 (02)
  • [43] The Role of Endoplasmic Reticulum in Lipotoxicity during Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Pathogenesis
    Venkatesan, Nanditha
    Doskey, Luke C.
    Malhi, Harmeet
    AMERICAN JOURNAL OF PATHOLOGY, 2023, 193 (12): : 1887 - 1899
  • [44] Subclinical myocardial fibrosis is related to disease severity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
    Nabilou, Puria
    Wiese, Signe
    Hetland, Liv
    Werge, Mikkel
    Thing, Mira
    Rashu, Elias
    Junker, Anders
    Barlose, Mads
    Siebner, Hartwig
    Moller, Soren
    Bendtsen, Flemming
    Gluud, Lise Lotte
    Hove, Jens
    JOURNAL OF HEPATOLOGY, 2024, 80 : S555 - S555
  • [45] THE MOLECULAR BASIS OF THYROID HORMONE RESCUE OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN MICE
    Ramanathan, Raghu
    Johnson, Sarah
    Ibdah, Jamal A.
    GASTROENTEROLOGY, 2024, 166 (05) : S1642 - S1642
  • [46] Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Singh, Avneet
    Buckholz, Adam
    Kumar, Sonal
    Newberry, Carolyn
    NUTRIENTS, 2024, 16 (05)
  • [47] NAFLD vs MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)-Why the Need for a Change of Nomenclature?
    Gastaldelli, Amalia
    Newsome, Philip N.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2025,
  • [48] Effects of Selected Food Additives on the Gut Microbiome and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Jarmakiewicz-Czaja, Sara
    Sokal-Dembowska, Aneta
    Filip, Rafal
    MEDICINA-LITHUANIA, 2025, 61 (02):
  • [49] Oral Health Characteristics in US Adults With and Without Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Ogbu, Chukwuemeka E.
    Goel, Abhishek
    Ogbu, Stella
    Umerah, Chinazor
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1454 - S1454
  • [50] Exploratory Role of Flavonoids on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a South Italian Cohort
    Bonfiglio, Caterina
    Tatoli, Rossella
    Donghia, Rossella
    Guido, Davide
    Giannelli, Gianluigi
    ANTIOXIDANTS, 2024, 13 (11)